Canada Vascular

Cerebrovascular Disease

Background

How Can Carotid Artery Disease Be Diagnosed?

Treatment Options

How Can I Get Screened & Treated for Cerebrovascular Disease?

Common Questions & Answers

Bibliography

 

 


Bibliography

  1. Johnston SC, Gress DR, Browner WS, Sidney S. Short-term Prognosis After Emergency Department Diagnosis of TIA. JAMA, 2000; 284:2901-2906.
  2. Goldstein LB, Adams R, Becker K, Furberg CD, Gorelick PB, Hademenos G, Hill M, Howard G, Howard VJ, Jacobs B, Levine SR, Mosca L, Sacco RL, Sherman DG, Wolf PA, Zoppo GJ. Primary Prevention of Ischemic Stroke. A Statement for Healthcare Professionals From the Stroke Council of the American Heart Association. Stroke, 2001; 32:280-299.
  3. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue Plasminogen Activator for Acute Ischemic Stroke. The New England Journal of Medicine, 1995; 333: 1581-1587.
  4. Marler JR, Tilley BC, Lu M, Brott TG, Lyden PC, Grotta JC, Broderick JP, Levine SR, Frankel MP, Horowitz SH, Haley EC, Lewandowski CA, Kwiatkowski TP, for the NINDS rt-PA Stroke Study Group. Early stroke treatment associated with better outcome. The NINDS rt-PA Stroke Study. Neurology, 2000; 55:1649-1655.
  5. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, Pessin M, Ahuja A, Callahan F, Clark WM, Silver F, Rivera F, for the PROACT Investigators. JAMA, 1999; 282:2003-2011.
  6. Tomsick T, Brott T, Barsan W, Broderick J, Haley EC, Spiker J and Khoury J. Prognostic Value of the Hyperdense Middle Cerebral Artery Sign and Stroke Scale Score before Ultraearly Thrombolytic Therapy. AJNR, 1996; 17:79-85.
  7. Connors JJ. Interventional Stroke Therapy: The Potential Benefit of Direct Intra-Arterial Infusion. XX
  8. del Zoppo GJ, Higashida RT, Furlan AJ, Pessin MS, Rowley HA, Gent M, DSc, and the PROACT Investigators. PROACT: A Phase II Randomized Trial of Recombinant Pro-Urkinase by Direct Arterial Delivery in Acute Middle Cerebral Artery Stroke. Stroke, 1998; 29:4-11.
  9. Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous Tissue-Type Plasminogen Activator for Treatment of Acute Stroke. The Standard Treatment with Alteplase to Reverse Stroke (STARS) Study. JAMA, 2000; 283:1145-1150.
  10. Wang DZ, Rose JA, Honings DS, Garwacki DJ, Milbrandt JC, for the OSF Stroke Team. Treating Acute Stroke Patients with Intravenous tPA. The OSF Stroke Network Experience. Stroke, 2000; 31:77-81.
  11. Lenzer J. Alteplase for stroke: money and optimistic claims buttress the "brain attack" campaign. BMJ, 2002; 324: 723-729.
  12. Lenzer J, Warlow C, Saver JL, Kidwell CS, Starkman S. Alteplase for stroke: money and optimistic claims buttress the "brain attack" campaign. Commentary: Who pays the guideline writers?. Commentary: Thrombolysis in stroke: it works! XX
  13. Hill MD, Barber PA, Demchuk AM, Newcommon NJ, Cole-Haskayne A, Ryckborst K, Sopher L, Button A, Hu W, Hudon ME, Morrish W, Frayne R, Sevick RJ, Buchan AM. Acute Intravenous-Intra-Arterial Revascularization Therapy for Sever Ischemic Stroke. Stroke, 2002; 33:279-282.
  14. Counsell C, Sandercock P. Low-Molecular-Weight Heparins or Heparinoids Versus Standard Unfranctionated Heparin for Acute Ischemic Stroke (Chochrane Review). Stroke, 2002; 33:1925-1926.
  15. Moonis M, Fisher M. Considering the Role of Heparin and Low-Molecular-Weight Heparins in Acute Ischemic Stroke. Stroke, 2002: 33: 1927-1933.
  16. Coull BM, Williams LS, Goldstein LB, Meschia JF, Heitzman D, Chaturvedi S, Johnston KC, Starkman S, Morgenstern LB, Wilterdink JL, Levine SR, Saver JL. Anticoagulants and Antiplatelet Agents in Acute Ischemic Stroke. Report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a Division of the American Heart Association). Stroke, 2002; 33:1934-1942.
  17. Adams HP. Emergent Use of Anticoagulation for Treatment of Patients With Ischemic Stroke. Stroke, 2002; 33:856-861.
  18. Muir KW, Roberts M. Thrombolytic Therapy for Stroke. A Review with Particular Reference to Elderly Patients. Drugs & Aging, 2000; January:41-54
  19. Coull BM, Williams LS, Goldstein LB, Meschia JF, Heitzman D, Chaturvedi S, Johnston KC, Starkman S, Morgenstern LB, Wilterdink JL, Levine SR, Saver JL. Anticoagulants and Antiplatelet Agents in Acute Ischemic Stroke. Report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a Division of the American Heart Association). Stroke, 2002; 33:1934-1942.
  20. McNamara R. AAEM Position Statement of the Use of Intravenous Thromblytic Therapy in the Treatment of Stroke. XX
  21. Uraneck K. ACEP Crafts tPA For Stroke Policy. Emergency Medicine Community Divided Over Drug’s Use. XX
  22. The American College of Emergency Physicians (ACEP). Use of Intravenous tPA for the Management of Acute Stroke in the Emergency Department. XX
  23. The CAEP Committee on Thrombolytic Thearpy for Acute Ischemic Stroke. Position Statement on Thrombolytic Therapy for Acute Ischemic Stroke. XX
  24. Higashida R, Connors JJ. Should Interventional Radiologists Be Involved in Acute Stroke Intervention? Re: Emergency Interventional Stroke Therapy: A Statement from the American Society of Interventional and Therapeutic Neuroradiology and the Society of Cardiovascular & Interventional Radiology. SCVIR, 2001; February:145-146.
  25. Connors JJ, Wojak JC. Percutaneous transluminal angioplasty for intracranial atherosclerotic lesions: evolution of technique and short-term results. J. Neurosurg, 1999; 91:415-422.
  26. Chimowitz MI, Kokkinos J, Strong J, Brown MB, Levine SR, Silliman S, Pessin MS, Weichel E, Sila CA, Furlan AJ, Kargman DE, Sacco RL, Wityk RJ, Ford G, Fayad PB, for the Warfarin-Aspirin Symptomatic Intracranial Disease Study Group. The Warfarin-Aspirin Symptomatic Intracranial Disease Study. Neurology, 1995: 45: 1488-1493.
  27. Connors JJ, Wojack JC. Intracranial Angioplasty. The Journal of Invasive Cardiology, 1998; 10:298-303.
  28. Thija VN, Albers GW. Symptomatic intracranial atherosclerosis. Outcome of patients who fail antithrombotic therapy. Neurology, 2000; 55:1-x.
  29. The Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) Study Group. Prognosis of Patients With Symptomatic Vertebral or Basilar Artery Stenosis. Stroke, 1998; 29:1389-1392.
  30. Chaloupka JC, Weigele JB, Mangla S, Lesley WS. Cerebrovascular Angioplasty and Stenting for the Prevention of Stroke. Current Neurology and Neuroscience Reports, 2001; 1:39-53.
  31. The EC/IC Bypass Study Group. Failure of Extracranial;-Intracranial Arterial Bypass to Reduce the Risk of Ischemic Stroke. Results of an International Randomized Trial. The New England Journal of Medicine, 1985; 313:1191-1199.
  32. Guthikonda M, Guyot LL, Diaz FG. Future of extracranial-intracranial bypass. Neurological Research, 2002; 24:S80-S83.
  33. Gomez CR, Misra VK, Liu MW, Wadlington VR, Terry JB, Tulyapronchote R, Campbell MS. Elective Stention of Symptomatic Basilar Artery Stenosis. Stoke, 2000; 31:95-99.
  34. Sacco RL, Elkind MS. Update on Antiplatelet Therapy for Stroke Prevention. Arch Intern Med, 2000; 160: 1579-1582.
  35. Kaplan ED, Sacco RL. Selection of Anticoagulants or Antiplatelet-aggregating Agents for Prevention of Stroke. Current Neurology and Neuroscience Reports, 2002; 2:31-37.
  36. Alexander G, Turpie G. Successors to heparin: New antihrombotic agents. American Heart Journal, 1997; 134:S71-S77.
  37. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and Thrombolytic Therapy for Ischemic Stroke. Chest, 2001; 119: 300S-320S.
  38. Gorelick PB. Stroke Prevention Therapy Beyond Antithrombotics: Unifying Mechanisms in Ischemic Stroke Pathogenesis and Implications for Therapy. An Invited Review. Stroke, 2002; 33:862-875.
  39. Selnes OA, McKhann GM. Coronary-Artery Bypass Surgery and the Brain. The New England Journal of Medicine, 2001; 334:451-452.
  40. Newman MF, Kirchner JL, Phillips-Bute B, Gaver V, Grocott H, Jones RH, Mark DB, Reves JG, Blumenthal JA, for the Neurological Outcome Research Group and the Cardiothoracic Anesthesiology Research Endeavors Investigators. The New England Journal of Medicine, 2001; 344: 395-402.
  41. Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, Franklin BA, Goldstein LB, Greenland P, Grundy SM, Hong Y, Miller NH, Lauer RM, Ockene IS, Sacco RL, Sallis JF, Smith SC, Stone NJ, Taubert KA. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update. Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. Circulation, 2002; 106:388-391.
  42. Cundiff DK. Thrombolysis for Acute Myocardial Infarction: Drug Review. XX
  43. Patrono C, Coller B, Dalen JE, Dalen JE, Fitzgerald GA, Fuster V, Gent M, Hirsh J, Roth G. Platelet-Active Drugs. The Relationships Among Dose, Effectiveness, and Side Effects. Chest, 2000; 119:39S-63S.
  44. Hirsh J, Anand SS, Halperin JL, Fuster V. Guide to Anticoagulant Therapy: Heparin. A Statement for Healthcare Professionals From the American Heart Association. Circulation, 2000; 103:2994-3018.
  45. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and Low-Molecular-Weight Heparin. Mechanisms of Acton, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety. Chest, 2001; 119:64S-94S.
  46. Adams HP, Brott TG, Crowell RM, Furlan AJ, Gomez CR, Grotta J, Helgason CM, Marler JR, Woolson RF, Zivin JA, Feinberg W, Mayberg M, Ex Officio Members. Guidelines for the Management of Patients With Acute Ischemic Stroke. A Statement for Healthcare Professional From a Special Writing Group of the Stroke Council, American Heart Association. Stroke, 1994; 25:1901-1914.
  47. Adams HP, Brott TG, Furlan AJ, Gomez CR, Grotta J, Helgason CM, Kwiatkowski T, Lyden PD, Marler JR, Torner J, Feinberg W, Mayberg M, Theis W, Ex Officio Members. Guidelines for Thrombolytic Therapy for Acute Stroke: A Supplement to the Guidelines for the Management of Patients With Acute Ischemic Stroke. A Statement for Healthcare Professionals From a Special Writing Group of the Stroke Council, American Heart Association. XX
  48. Culebras A, Kase CS, Masdeu JC, Fox AJ, Bryan RN, Grossman B, Lee DH, Adams HP, Thies W, Ex Officio Members. Practice Guidelines for the Use of Imaging in Transient Ischemic Attacks and Acute Stroke. A Report of the Stroke Council, American Heart Association. XX
  49. Albers GW, Hart RG, Lutsep HL, Newell DW, Sacco RL. Supplement to the Guidelines for the Management of Transient Ischemic Attacks. A Statement From the Ad Hoc Committee on Guidelines for the Management of Transient Ischemic Attacks, Stroke Council, American Heart Association. Stroke, 1999: 30:2502-2511.
  50. Mayberg MR, Batjer HH, Dacey R, Diringer M, Haley C, Heros RC, Sernau LS, Torner J, Adams HP, Feinberg W, Theis W, Ex Officio Members. Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage. A Statement for Healthcare Professionals From a Special Writing Group of the Stroke Council, American Heart Association.
  51. Broderick JP, Adams HP, Barsan W, Feinberg W, Feldmann E, Grotta J, Kase C, Krieger D, Mayberg M, Tilley B, Zabramski JM, Zuccarello M. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage. A Statement for Healthcare Professionals From a Special Writing Group of the Stroke Council, American Heart Association. Stroke, 1999; 30:905-915.
  52. Wolf PA, Clagett GP, Easton D, Goldstein LB, Gorelick PB, Kelly-Hayes M, Sacco RL, Whisnant JP. Preventing Ischemic Stroke in Patients With Prior Stroke and Transient Ischemic Attack. A Statement for Healthcare Professionals From the Stroke Council of the American Heart Association. Stroke, 1999; 30:1991-1994.
  53. Kelly-Hayes M, Robertson JT, Broderick JP, Duncan PW, Hershey LA, Roth EJ, Thies WH, Trombly CA. The American Heart Association Stroke Outcome Classification. Stroke, 1998; 29:1274-1280.
  54. Rodriquez DV. Cerebrovascular Occlusions. XX
  55. Brott T, Bogousslavsky J. Treatment of Acute Ischemic Stroke. The New England Journal of Medicine, 2000; 343:710-722.
  56. Mohr JP, Thompson JLP, Lazar RM, Levin B, Sacco RL, Furie KL, Kistler JP, Albers GW, Pettigrew LC, Adams HP, Jackson CM, Pullicino P, for the Warfarin-Aspirin Recurrent Stroke Study Group. A Comparison of Warfarin and Aspirin for the Prevention of Recurrent Ischemic Stroke. The New England Journal of Medicine, 2001; 345:1444-1451.
  57. Mohr JP, Thompson JLP, Lazar RM, Levin B, Sacco RL, Furie KL, Kistler JP, Albers GW, Pettigrew LC, Adams HP, Jackson CM, Pullicino P, for the Warfarin-Aspirin Recurrent Stroke Study Group. A Comparison of Warfarin and Aspirin for the Prevention of Recurrent Ischemic Stroke. The New England Journal of Medicine, 2001; 345: 1444-1451.
[Top]
Copyright 2009 Canadavascular.com. All Right Reserved.